Financial Performance - Operating income for the first nine months reached CNY 243,760,117.03, a growth of 43.58% compared to the same period last year[6] - Net profit attributable to shareholders increased by 65.10% to CNY 57,222,539.23 year-on-year[6] - Basic earnings per share rose by 28.21% to CNY 0.50[6] - Total operating revenue for the first nine months of 2018 reached RMB 243,760,117.03, a 43.5% increase compared to RMB 169,771,067.73 in the same period last year[26] - Operating profit for Q3 2018 was RMB 40,977,348.05, up 55.2% from RMB 26,415,684.26 in Q3 2017[27] - Net profit attributable to the parent company for the first nine months of 2018 was RMB 57,222,539.23, representing a 65.0% increase from RMB 34,659,759.04 in the previous year[28] - The total profit for the first nine months of 2018 was RMB 68,824,068.37, a 71.5% increase from RMB 40,091,883.79 in the same period last year[27] Cash Flow - Net cash flow from operating activities surged by 76.78% to CNY 121,738,047.54 compared to the same period last year[6] - Cash inflow from operating activities totaled CNY 354,503,510.40, compared to CNY 246,738,591.20 in the previous year, indicating a year-over-year increase of about 43.6%[33] - The net cash flow from operating activities was CNY 121,738,047.54, up from CNY 68,862,535.31, reflecting an increase of approximately 76.7%[33] - Total cash outflow from investing activities was CNY 676,598,682.52, leading to a net cash flow from investing activities of -CNY 221,332,857.99, compared to -CNY 14,494,945.58 last year[34] - The company reported cash inflow from sales of goods and services of CNY 349,546,851.86, compared to CNY 244,547,797.80 in the same period last year, marking an increase of about 42.9%[33] Assets and Liabilities - Total assets increased by 16.74% to CNY 1,098,333,994 compared to the end of the previous year[6] - Total liabilities grew to CNY 499,781,992.69 from CNY 383,084,840.96, marking an increase of around 30.6%[20] - Current assets rose to CNY 700,694,058.91, up from CNY 597,449,179.92, indicating an increase of about 17.25%[18] - Inventory increased significantly to CNY 129,874,750.97 from CNY 92,236,632.38, reflecting a growth of approximately 40.8%[18] - The company’s total equity increased by 40.58% to RMB 114,994,600.00, mainly due to equity incentives and stock dividends received[14] Shareholder Information - The total number of shareholders reached 6,569[11] - The largest shareholder, Feng Yuxia, holds 28.44% of the shares, with 14,252,000 shares pledged[11] Expenses - Operating costs increased by 54.45% to RMB 113,848,500.97, corresponding to the rise in service income[15] - Management expenses grew by 45.01% to RMB 53,273,288.35, mainly due to higher labor costs[15] - Research and development expenses for the first nine months of 2018 amounted to RMB 18,188,639.43, slightly down from RMB 19,059,981.71 in the previous year[27] Other Financial Metrics - The weighted average return on equity decreased by 1.62 percentage points to 9.88%[6] - Government subsidies related to normal business operations amounted to CNY 8,112,861.58 for the year-to-date[8] - The company reported a significant increase in other receivables by 311.17% to RMB 4,736,936.03, due to increased deposits and interest receivables[14] - Prepayments rose by 54.09% to RMB 7,698,495.57, attributed to increased procurement[14]
昭衍新药(603127) - 2018 Q3 - 季度财报